REGN:NASDAQRegeneron Pharmaceuticals, Inc. Analysis

Regeneron (REGN) trades around $635, roughly 31% below its DCF‑derived fair value of $957, offering a sizable upside. The stock’s PE of 15.5x is well under the biotech industry average of 27.9x, while the forward PE contracts to 11.8x, underscoring its relative cheapness. Revenue is expanding at a healthy 19% YoY with robust margins (gross ~44%, operating ~21%) and a strong cash pile of $8.75 bn versus $2.71 bn of debt, supporting the modest 0.59% dividend yield and a low payout ratio of 8.7%. Recent material news adds momentum: the FDA approved REGN’s gene‑therapy Otarmeni for a rare form of deafness, and a new collaboration with CytomX was announced, potentially worth up to $4 bn. However, a Citigroup downgrade from Buy to Hold introduces a short‑term caution flag.
Technical indicators show the price sitting below the 20‑day (652.9), 50‑day (707.1) and 200‑day (695.9) moving averages, indicating a lingering downtrend, yet the MACD histogram turned positive and the RSI sits near 41, suggesting limited downside pressure. With a support level around $591 and resistance near $731, the stock has room to rebound. Volatility remains elevated at 42% (30‑day) but beta is modest (0.48), tempering systematic risk. Overall, the blend of undervaluation, strong fundamentals, and pipeline catalysts points to a compelling medium‑ to long‑term buying case, while short‑term positioning should remain cautious.